205 related articles for article (PubMed ID: 28981198)
1. Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice.
Tersteeg C; Joly BS; Gils A; Lijnen R; Deckmyn H; Declerck PJ; Plaimauer B; Coppo P; Veyradier A; Maas C; De Meyer SF; Vanhoorelbeke K
J Thromb Haemost; 2017 Dec; 15(12):2432-2442. PubMed ID: 28981198
[TBL] [Abstract][Full Text] [Related]
2. Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy.
Tersteeg C; de Maat S; De Meyer SF; Smeets MW; Barendrecht AD; Roest M; Pasterkamp G; Fijnheer R; Vanhoorelbeke K; de Groot PG; Maas C
Circulation; 2014 Mar; 129(12):1320-31. PubMed ID: 24449821
[TBL] [Abstract][Full Text] [Related]
3. Platelet rescue by macrophage depletion in obese ADAMTS-13-deficient mice at risk of thrombotic thrombocytopenic purpura.
Geys L; Roose E; Scroyen I; Rottensteiner H; Tersteeg C; Hoylaerts MF; Vanhoorelbeke K; Lijnen HR
J Thromb Haemost; 2018 Jan; 16(1):150-163. PubMed ID: 29121438
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura.
Feys HB; Vandeputte N; Palla R; Peyvandi F; Peerlinck K; Deckmyn H; Lijnen HR; Vanhoorelbeke K
J Thromb Haemost; 2010 Sep; 8(9):2053-62. PubMed ID: 20553378
[TBL] [Abstract][Full Text] [Related]
5. Proteolytic inactivation of ADAMTS13 by plasmin in human plasma: risk of thrombotic thrombocytopenic purpura.
Shin Y; Miyake H; Togashi K; Hiratsuka R; Endou-Ohnishi K; Imamura Y
J Biochem; 2018 May; 163(5):381-389. PubMed ID: 29228282
[TBL] [Abstract][Full Text] [Related]
6. Plasmin-cleaved von Willebrand factor as a biomarker for microvascular thrombosis.
El Otmani H; Frunt R; Smits S; Barendrecht AD; de Maat S; Fijnheer R; Lenting PJ; Tersteeg C
Blood; 2024 May; 143(20):2089-2098. PubMed ID: 38271661
[TBL] [Abstract][Full Text] [Related]
7. Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura.
Wada H; Kaneko T; Ohiwa M; Tanigawa M; Hayashi T; Tamaki S; Minami N; Deguchi K; Suzuki K; Nakano T
Am J Hematol; 1993 Oct; 44(2):101-5. PubMed ID: 8266913
[TBL] [Abstract][Full Text] [Related]
8. Mechanism underlying severe deficiency of plasma ADAMTS-13 activity in immune thrombotic thrombocytopenic purpura.
Zheng XL
J Thromb Haemost; 2024 May; 22(5):1358-1365. PubMed ID: 38360215
[TBL] [Abstract][Full Text] [Related]
9. von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura.
Moake JL
Semin Hematol; 2004 Jan; 41(1):4-14. PubMed ID: 14727254
[TBL] [Abstract][Full Text] [Related]
10. Loss of von Willebrand factor high-molecular-weight multimers at acute phase is associated with detectable anti-ADAMTS13 IgG and neurological symptoms in acquired thrombotic thrombocytopenic purpura.
Béranger N; Benghezal S; Savigny S; Capdenat S; Joly BS; Coppo P; Stepanian A; Veyradier A
Thromb Res; 2019 Sep; 181():29-35. PubMed ID: 31330376
[TBL] [Abstract][Full Text] [Related]
11. A role for tissue plasminogen activator in thrombotic thrombocytopenic purpura.
Hoirisch-Clapauch S; Nardi AE
Med Hypotheses; 2014 Dec; 83(6):747-50. PubMed ID: 25459148
[TBL] [Abstract][Full Text] [Related]
12. Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics.
Saha M; McDaniel JK; Zheng XL
J Thromb Haemost; 2017 Oct; 15(10):1889-1900. PubMed ID: 28662310
[TBL] [Abstract][Full Text] [Related]
13. Platelet reactive conformation and multimeric pattern of von Willebrand factor in acquired thrombotic thrombocytopenic purpura during acute disease and remission.
Lotta LA; Lombardi R; Mariani M; Lancellotti S; De Cristofaro R; Hollestelle MJ; Canciani MT; Mannucci PM; Peyvandi F
J Thromb Haemost; 2011 Sep; 9(9):1744-51. PubMed ID: 21726405
[TBL] [Abstract][Full Text] [Related]
14. Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity.
Mori Y; Wada H; Gabazza EC; Minami N; Nobori T; Shiku H; Yagi H; Ishizashi H; Matsumoto M; Fujimura Y
Transfusion; 2002 May; 42(5):572-80. PubMed ID: 12084165
[TBL] [Abstract][Full Text] [Related]
15. Thrombin generation in patients with thrombotic thrombocytopenic purpura.
Takahashi H; Tatewaki W; Wada K; Shibata A
Am J Hematol; 1989 Dec; 32(4):255-7. PubMed ID: 2479264
[TBL] [Abstract][Full Text] [Related]
16. Prevention of relapse in patients with acquired thrombotic thrombocytopenic purpura undergoing elective surgery: a case series.
Arcudi S; Ferrari B; Pontiggia S; Tufano A; Artoni A; Mancini I; Peyvandi F
J Thromb Haemost; 2019 Mar; 17(3):492-498. PubMed ID: 30629316
[TBL] [Abstract][Full Text] [Related]
17. Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura.
Thomas MR; de Groot R; Scully MA; Crawley JT
EBioMedicine; 2015 Aug; 2(8):942-52. PubMed ID: 26425702
[TBL] [Abstract][Full Text] [Related]
18. Generation of Anti-Murine ADAMTS13 Antibodies and Their Application in a Mouse Model for Acquired Thrombotic Thrombocytopenic Purpura.
Deforche L; Tersteeg C; Roose E; Vandenbulcke A; Vandeputte N; Pareyn I; De Cock E; Rottensteiner H; Deckmyn H; De Meyer SF; Vanhoorelbeke K
PLoS One; 2016; 11(8):e0160388. PubMed ID: 27479501
[TBL] [Abstract][Full Text] [Related]
19. The von Willebrand factor-cleaving protease (ADAMTS-13) and the diagnosis of thrombotic thrombocytopenic purpura (TTP).
Kremer Hovinga JA; Studt JD; Lämmle B
Pathophysiol Haemost Thromb; 2003 Sep-2004 Dec; 33(5-6):417-21. PubMed ID: 15692254
[TBL] [Abstract][Full Text] [Related]
20. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura.
Furlan M; Robles R; Solenthaler M; Lämmle B
Blood; 1998 Apr; 91(8):2839-46. PubMed ID: 9531594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
